Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 343 across all filing types
Latest filing 2025-10-07 Regulatory Filings
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release from MaaT Pharma announcing positive safety results from an interim analysis of a clinical trial (PHOEBUS). It details the findings of the Data Safety Monitoring Board (DSMB) regarding the MaaT033 drug candidate. Since this is a general regulatory announcement regarding clinical trial progress and does not fit into specific financial reporting categories like 10-K or IR, and is not a report publication announcement, it falls under the general regulatory filing category.
2025-10-07 English
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 100% confidence The document is a press release from MaaT Pharma announcing positive safety results from a DSMB (Data Safety Monitoring Board) review for their Phase 2b clinical trial (PHOEBUS). It details the trial progress, safety profile, and future outlook. This type of announcement regarding clinical trial milestones and regulatory/safety committee outcomes is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement regarding operational progress that does not fit into specific financial reporting categories like 10-K or IR.
2025-10-07 French
Franchissements de seuils
Major Shareholding Notification Classification · 100% confidence The document is an official notice from the AMF (Autorité des marchés financiers) regarding the crossing of shareholding thresholds (franchissements de seuils) by Symbiosis LLC in the company MAAT PHARMA. This type of regulatory disclosure, which reports changes in significant share ownership levels, falls directly under the 'Major Shareholding Notification' category.
2025-10-06 French
Rapport Financier Semestriel - S1 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2025' (Half-Year Financial Report as of June 30, 2025). It contains a detailed summary, management report, interim financial statements (balance sheet, income statement, cash flow), and notes to the financial statements. It also includes an 'Attestation du responsable' (Officer Certification). As it is a comprehensive financial report for a period shorter than a full fiscal year (six months) and contains substantive financial data, it is classified as an Interim/Quarterly Report. H1 2025
2025-09-17 French
Rapport Financier Semestriel 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2025' (Semi-Annual Financial Report as of June 30, 2025) for MaaT Pharma SA. It contains a summary, a management report (Rapport d'activité), interim financial statements (Etats financiers semestriels résumés), and an audit report reference. This document constitutes a comprehensive interim financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2025
2025-09-17 French
Rapport Semestriel 2025
Interim / Quarterly Report Classification · 100% confidence The document is a 'Rapport Financier Semestriel' (Half-Year Financial Report) for MaaT Pharma SA for the period ending June 30, 2025. It contains a comprehensive summary, management report (Rapport d'activité), interim financial statements (Etats financiers semestriels résumés), and an audit report (Rapport des commissaires aux comptes). This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2025
2025-09-17 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.